What Lexaria Bioscience Corp.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 1 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 100,000 |
| Net activity | +0 | −100,000 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Bunka Christopher | Director | Mar 17 | Gift · G | −100,000 | — | — | 273,543 |
| Bunka Christopher | Director | Jul 30 | Open-market buy · P | +11,900 | $0.91 | +$10.9K | 281,912 |
| Christopher Richard | Chief Executive Officer | Jul 29 | Open-market buy · P | +15,000 | $0.91 | +$13.6K | 65,000 |
| Docherty John Martin | President & CSO | Jul 29 | Open-market buy · P | +5,376 | $0.93 | +$4.99K | 5,376 |
| McKechnie William Edward | Director | Jul 29 | Open-market buy · P | +5,000 | $0.91 | +$4.53K | 18,191 |
| Carle Vanessa | Secretary | Jul 29 | Open-market buy · P | +750 | $0.91 | +$683 | 750 |
| Bunka Christopher | Director | Jul 29 | Open-market buy · P | +15,600 | $0.92 | +$14.4K | 270,012 |
| Bunka Christopher | Director | Jan 07 | Grant / award · A | +100,000 | — | — | 373,543 |
| Christopher Richard | Chief Executive Officer | Dec 03 | Open-market buy · P | +27,172 | $2.47 | +$67.2K | 50,000 |
| Christopher Richard | Chief Executive Officer | Dec 02 | Open-market buy · P | +22,828 | $2.24 | +$51.2K | 22,828 |
| Turkel Catherine C. | Director | Aug 12 | Open-market buy · P | +1,600 | $3.13 | +$5.01K | 3,100 |
| Carle Vanessa | Secretary | Jul 31 | Open-market sale · S | −2,567 | $4.00 | −$10.3K | 0 |
| Carle Vanessa | Secretary | May 14 | Exercise / conversion · M | +2,500 | $1.15 | +$2.88K | 2,567 |
| Turkel Catherine C. | Director | Feb 09 | Open-market buy · P | +1,500 | $2.84 | +$4.27K | 1,500 |
| Downey Gregory | Chief Financial Officer | Oct 14 | Open-market buy · P | +121 | $2.09 | +$253 | 1,954 |
| Bunka Christopher | Chief Executive Officer | Oct 13 | Open-market buy · P | +16,600 | $2.10 | +$34.9K | 254,412 |
| Bunka Christopher | Chief Executive Officer | Oct 12 | Open-market buy · P | +21,900 | $1.99 | +$43.5K | 237,812 |
| Reese Albert L Jr | Director | May 24 | Grant / award · A | +5,000 | $1.96 | +$9.79K | 10,917 |
| Reese Albert L Jr | Director | May 20 | Grant / award · A | +1,799 | $2.01 | +$3.61K | 5,917 |
| Reese Albert L Jr | Director | May 19 | Grant / award · A | +1,501 | $2.01 | +$3.02K | 4,118 |
Loading...